Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 22 citing articles:

Treatment of extranodal NK/T-cell lymphoma: From past to future
Zheng Yan, Shuna Yao, Zhizhong Wang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 13
Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma
Xi Chen, Wanchun Wu, Wenwen Wei, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 16
Epigenetic alterations and advancement of lymphoma treatment
Shuhui Zhuang, Zhaobo Yang, Zhuangzhuang Cui, et al.
Annals of Hematology (2023) Vol. 103, Iss. 5, pp. 1435-1454
Closed Access | Times Cited: 7
Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy
Mohammadsaleh Jahangir, Omid Yazdani, Mohammad Saeed Kahrizi, et al.
Cancer Cell International (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 9
Case report: Targeting the PD-1 receptor and genetic mutations validated in primary histiocytic sarcoma with hemophagocytic lymphohistiocytosis
Yan Zhao, Yating Deng, Yi Jiang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 5
Immunotyping of peripheral blood lymphocytes by flow cytometry reveals Th cell as a potential prognostic biomarker for extranodal NK/T-cell lymphoma
Fei Qi, Yuce Wei, Meng Wu, et al.
Annals of Hematology (2024) Vol. 103, Iss. 5, pp. 1643-1653
Closed Access | Times Cited: 1
First-Line Chemoradiation With or Without Chidamide (Tucidinostat) in Patients With Intermediate- and High-Risk Early-Stage Extranodal Nasal-Type Natural Killer/T-Cell Lymphoma: A Randomized Phase 2 Study in China
Yue Chai, Bo Chen, Fei Qi, et al.
International Journal of Radiation Oncology*Biology*Physics (2022) Vol. 113, Iss. 4, pp. 833-844
Closed Access | Times Cited: 9
Advances and challenges of immunotherapies in NK/T cell lymphomas
Ling He, Na Chen, Lei Dai, et al.
iScience (2023) Vol. 26, Iss. 11, pp. 108192-108192
Open Access | Times Cited: 4
Acetylation in Tumor Immune Evasion Regulation
Jun Lu, Xiang He, Lijuan Zhang, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 10
Sintilimab combined with chidamide in the treatment of extranodal nature killer/T-cell lymphoma with secondary hemophagocytic lymphohistiocytosis: Two case reports and literature review
Qingyuan Xu, Haiyan Yang, Meiwei Li, et al.
Medicine (2022) Vol. 101, Iss. 38, pp. e30731-e30731
Open Access | Times Cited: 6
Chidamide and sintilimab combination in diffuse large B-cell lymphoma progressing after chimeric antigen receptor T therapy
Yuanyuan Hao, Panpan Chen, Xianggui Yuan, et al.
World Journal of Clinical Cases (2022) Vol. 10, Iss. 19, pp. 6555-6562
Open Access | Times Cited: 5
Sintilimab and Chidamide for Refractory Transformed Diffuse Large B Cell Lymphoma: A Case Report and A Literature Review
Chao Chen, Wei Zhang, Daobin Zhou, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 7
Combination of atezolizumab and chidamide to maintain long-term remission in refractory metastatic extranodal natural killer/T-cell lymphoma: A case report
Juan Wang, Yongsheng Gao, Kun Xu, et al.
World Journal of Clinical Cases (2022) Vol. 10, Iss. 5, pp. 1609-1616
Open Access | Times Cited: 4
Case report: Mutation evolution in a patient with TdT positive high grade B cell lymphoma with MYC and BCL2 rearrangements following the treatment of concurrent follicular lymphoma and diffuse large B-cell lymphoma
Fen Zhang, Yu Chen, Qian Cui, et al.
Discover Oncology (2024) Vol. 15, Iss. 1
Open Access
Resistance mechanisms and potential therapeutic strategies in relapsed or refractory natural killer/T cell lymphoma
Chengji Wang, Liang Wang
Chinese Medical Journal (2024) Vol. 137, Iss. 19, pp. 2308-2324
Open Access
Immune Checkpoints and Their Inhibition in T-Cell Lymphomas
Jana Seňavová, Anežka Rajmonová, V. Herman, et al.
Folia Biologica (2024) Vol. 70, Iss. 3, pp. 123-151
Closed Access
Immune checkpoints in B-cell Lymphoma: Still an Unmet challenge from Basic research to clinical practice
Sijia Li, Yuanyuan Pan, Ruyu Ye, et al.
International Immunopharmacology (2024) Vol. 146, pp. 113717-113717
Closed Access
Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma
Mengya Zhong, Jinshui Tan, Guangchao Pan, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 5
Intensive therapy can improve long‐term survival in newly diagnosed, advanced‐stage extranodal NK/T‐cell lymphoma: A multi‐institutional, real‐world study
Yuce Wei, Fei Qi, Baomin Zheng, et al.
International Journal of Cancer (2023) Vol. 153, Iss. 9, pp. 1643-1657
Closed Access | Times Cited: 1
Chidamide combined with traditional chemotherapy for primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma: A case report
Zhendong He, Haiyan Yang, Shengsheng Zhou, et al.
World Journal of Clinical Cases (2022) Vol. 10, Iss. 4, pp. 1341-1348
Open Access | Times Cited: 2
Case Report: Outcome and Adverse Events of Anti-PD-1 Antibody Plus Chidamide for Relapsed/Refractory Sézary Syndrome: Case Series and A Literature Review
Chao Chen, Zhaorui Liu, Jie Liu, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 2
Multiple drugs

Reactions Weekly (2021) Vol. 1844, Iss. 1, pp. 304-304
Closed Access
Page 1

Scroll to top